B7-H3/IL-7Ra CAR T-cell therapy (Chulalongkorn University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameB7-H3/IL-7Ra CAR T-cell therapy (Chulalongkorn University)

Drug Alias Nameautologous cell therapy (Chulalongkorn University)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsNeuroprotectantsCD276 antigen modulators +[4]

TargetsCD276 antigenInterleukin-7 receptors

Therapy Area/IndicationsBrain Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryThailand

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesChulalongkorn University

China Registration ClassN/A

Develop Information

Active CompaniesChulalongkorn University

Inactive CompaniesN/A

Active IndicationsBrain Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A